RT Journal Article
SR Electronic
T1 WITHDRAWN: Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.24.24301555
DO 10.1101/2024.01.24.24301555
A1 Ross, Rachael K.
A1 Nunes, Edward V.
A1 Olfson, Mark
A1 Shulman, Matisyahu
A1 Krawczyk, Noa
A1 Stuart, Elizabeth A.
A1 Rudolph, Kara E.
YR 2024
UL http://medrxiv.org/content/early/2024/01/24/2024.01.24.24301555.abstract
AB This version of the manuscript and associated files have been removed owing to concerns of data privacy.Competing Interest StatementDeclarations of competing interest: Dr. Nunes has served as an investigator on NIH-funded studies that received donated medication or digital therapeutics from Alkermes, Braeburn, Camurus, Indivior, Chess Health, and Pear Therapeutics, and has served as a consultant without compensation to Alkermes, Camurus, Indivior, and Pear Therapeutics. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. Funding StatementThis study was funded by NIH NIDA 5R01DA056407Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Columbia University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes